Dr. Moreb's areas of specialization in the laboratory research are in drug resistance, gene expression, and cell biology. His research interests and activities have involved laboratory research focused on aldehyde dehydrogenases (ALDH) isozymes and their role in drug resistance of hematopoietic stem cells (HSC) as well as cancer cells and more recently as a possible marker for lung cancer stem cell. In addition, he is active in different clinical research projects. These involve different aspects of stem cell transplantation (SCT) including stem cell mobilization, engraftment, and the use of new methods to improve outcomes after autologous SCT (ASCT) for myeloma. Tandem transplants, post-transplant maintenance therapy, including adoptive immunotherapy and Phase I-III for Multiple Myeloma are his current areas of interest.

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Bristol Myers Squibb
Janssen Oncology

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811